ライフサイエンスコーパス: atrial septal defect

1 alvular aortic stenosis, and 2.8% for primum atrial septal defect.

2 One infant had an atrial septal defect.

3 undergo surgical repair of an ostium primum atrial septal defect.

4 22 patients and 10 control subjects with an atrial septal defect.

5 er responding to surgical closure of a large atrial septal defect.

6 gical approaches for simple lesions, such as atrial septal defect.

7 nt with tricuspid atresia and large secundum atrial septal defect.

8 in a large family with dominantly inherited atrial septal defect.

9 n of the great arteries, and ventricular and atrial septal defects.

10 ccluder for percutaneous closure of secundum atrial septal defects.

11 heart syndrome but inversely associated with atrial septal defects.

12 fety and efficacy of device closure of large atrial septal defects.

13 interaction affect muscular ventricular and atrial septal defects.

14 rmed on 9 kindreds with familial CHD, 4 with atrial septal defects, 2 with patent ductus arteriosus,

15 ich ventricular septal defects (22/47, 47%), atrial septal defects (20/47, 43%), patent ductus arteri

16 Principal features of IART circuits were atrial septal defect (4 patients), atriotomy (3 patients

17 ect, 3.3%; and 8) urinary tract infection in atrial septal defect, 6.4%.

18 5+/-14 years) with PHT and associated CHD (9 atrial septal defect, 7 ventricular septal defect, 4 tra

19 tion of the great arteries (8%), ventricular/atrial septal defects (8%), left ventricular outflow obs

20 Final QIs included: 8 for atrial septal defects; 9 for aortic coarctation; 12 for

21 In the presence of an acute atrial septal defect, a Qp/Qs ratio of 1.3+/-0.2 was mea

22 including aortic coarctation, ventricular or atrial septal defect, abnormal mitral valve, aortic root

23 ere at highest risk of IE in comparison with atrial septal defects (adjusted rate ratio, 95% confiden

24 phisms that confer greater susceptibility to atrial septal defect and atrioventricular septal defects

25 epilepticus, congestive heart failure due to atrial septal defect and hypernatremic dehydration due t

26 monary stenosis in 2 and subaortic membrane, atrial septal defect and mitral regurgitation in 1 patie

27 re moderate to large VSD in two patients and atrial septal defect and unlimited differential diagnosi

28 quarter of affected individuals, as well as atrial septal defect and ventricular septal defect.

29 iac malformations, including ventricular and atrial septal defects and a thin ventricular myocardium.

30 iations between carbon monoxide and isolated atrial septal defects and between ozone and isolated ven

31 athways may contribute to the development of atrial septal defects and bicuspid aortic valves.

32 onsistent in magnitude were detected between atrial septal defects and bromoform (aOR = 1.56; 95% CI:

33 Most cases of atrial septal defects and cardiomyopathy are not associa

34 nd, hence, is a candidate causative gene for atrial septal defects and cardiomyopathy.

35 domain, p.G115W, was identified in familial atrial septal defects and demonstrated decreased transac

36 tion factor, were reported to cause secundum atrial septal defects and result in atrioventricular (AV

37 al defect device for use in multifenestrated atrial septal defects and the fenestrated atrial septal

38 Antidiastole of coronary heart disease, atrial septal defect, and atrial fibrillation are made,

39 n autosomal dominant skeletal dysplasia with atrial septal defects, and familial total anomalous pulm

40 D (ie, excluding ventricular septal defects, atrial septal defects, and pulmonary valve stenosis) occ

41 duodenal atresia/stenosis (aOR = 2.48), and atrial septal defect (aOR = 1.37).

42 were positively associated with the risks of atrial septal defect (aORs ranging from 1.29 to 2.17), p

43 these pollutants and daily risks of secundum atrial septal defect, aortic coarctation, hypoplastic le

44 Most children with isolated atrial septal defects are free of symptoms, but the rate

45 Atrial septal defects are the third most common type of

46 defects (aRR, 0.85; 95% CI, 0.75-0.96), and atrial septal defects (aRR, 0.82; 95% CI, 0.69-0.95) but

47 370), left-sided lesions (n = 160), secundum atrial septal defect (ASD) (n = 71), and Ebstein's malfo

48 ht atrium to the right ventricle and both an atrial septal defect (ASD) and a ventricular septal defe

49 r (RV) volume after transcatheter closure of atrial septal defect (ASD) and to investigate factors th

50 Only one atrial septal defect (ASD) and two patent ductus arterio

51 We compared administrative data for atrial septal defect (ASD) and ventricular septal defect

52 e attacks is a complication of transcatheter atrial septal defect (ASD) closure.

53 x 10(-)(7)) with the risk of ostium secundum atrial septal defect (ASD) in the discovery cohort (N =

54 Secundum atrial septal defect (ASD) is a common congenital heart

55 A variety of transcatheter atrial septal defect (ASD) occluders are currently in us

56 Sinus venosus atrial septal defect (ASD) was the most common associate

57 eptal occluder (ASO) for closure of secundum atrial septal defect (ASD) with surgical closure.

58 MYH6 can cause an autosomal dominant form of atrial septal defect (ASD), whereas others have identifi

59 eptal occluder (HSO) with surgical repair of atrial septal defect (ASD).

60 owing isolated procedures: device closure of atrial septal defect (ASD); device closure of patent duc

61 use of permanent synthetic implants to close atrial septal defects (ASD) and patent foramen ovale (PF

62 form transcatheter closures of secundum type atrial septal defects (ASD) and to assess ASD size and c

63 m in the embryo and persistent ostium primum atrial septal defects (ASD) in approximately 20% of adul

64 Transcatheter closure of secundum atrial septal defects (ASD) using the Amplatzer septal o

65 attractive therapeutic option for congenital atrial septal defects (ASD).

66 phy (ICE) in guiding percutaneous closure of atrial septal defects (ASD).

67 fourth generation buttoned device in dosing atrial septal defects (ASDs) and to test the hypothesis

68 Atrial septal defects (ASDs) are a common human congenit

69 generations of closure devices for secundum atrial septal defects (ASDs) at a single institution.

70 tional dysregulation leads to development of atrial septal defects (ASDs) at high frequency.

71 Atrial septal defects (ASDs) can result from haploinsuff

72 rnelia de Lange syndrome-associated secundum atrial septal defects (ASDs) caused by NIPBL mutations,

73 Transcatheter closure of atrial septal defects (ASDs) has been feasible and succe

74 was to quantitate shunt flow volumes through atrial septal defects (ASDs) in a chronic animal model w

75 spected anomalous pulmonary veins (APVs) and atrial septal defects (ASDs) using fast cine magnetic re

76 buttoned device for transcatheter closure of atrial septal defects (ASDs).

77 sthesis for percutaneous closure of secundum atrial septal defects (ASDs).

78 went surgical correction of an ostium primum atrial septal defect at our institution at a mean age of

79 en <15 years) with large, isolated, secundum atrial septal defects (balloon-stretched diameter >/=34

80 septal defect (SVASD) differs from secundum atrial septal defect by its atrial septal location and i

81 ients undergoing the surgical creation of an atrial septal defect by the Blalock-Hanlon technique.

82 ven patients (6%) in the pitavastatin group (atrial septal defect, chronic obstructive pulmonary dise

83 alve procedure (9%), patent foramen ovale or atrial septal defect closure (23%), cardiac metastasecto

84 Between 2008 and 2012, atrial septal defect closure with the AMPLATZER Septal O

85 and frequent concomitant procedures such as atrial septal defect closure, arrhythmia surgery (the ma

86 enomic analyses of probands with heterotaxy, atrial septal defects, conotruncal, and left ventricular

87 Atrial septal defect device closure decreased Qp from 6.

88 already well-established techniques such as atrial septal defect device closure.

89 ed Amplatzer Ductal Occluder, the cribriform atrial septal defect device for use in multifenestrated

90 ed atrial septal defects and the fenestrated atrial septal defect device.

91 ar that evaluated the safety and efficacy of atrial septal defect devices, patent ductus occluders, a

92 oninvasive procedure to create or enlarge an atrial septal defect for the treatment of neonates with

93 Percutaneous treatment of inter-atrial septal defects has undergone exponential growth i

94 obese women had significantly higher ORs for atrial septal defects, hypoplastic left heart syndrome,

95 tachycardia (AT) after SR-CHD were studied (atrial septal defect in 6, tetralogy of Fallot in 4, and

96 m was suspected in four, or to close a large atrial septal defect in four) could be contacted.

97 l lymphopenia, intermittent neutropenia, and atrial septal defects in 3 members of a consanguineous k

98 pathophysiology, treatment, and outcomes of atrial septal defects in children and adult patients in

99 Atrial septal defect is one of the most common forms of

100 .I263V mutation in TLL1 was identified in an atrial septal defects kindred and is predicted to affect

101 ts with repaired "simple" lesions such as an atrial septal defect may not have normal survival if the

102 AV cushion defects including atrial septal defect, membranous VSD, and thickened valv

103 patients underwent repair of a secundum-type atrial septal defect (n=12) or patent foramen ovale (n=5

104 microm in aerodynamic diameter and isolated atrial septal defects (odds ratio = 2.27, 95% confidence

105 We identified a new locus linked with atrial septal defect on chromosome 14q12 in a large fami

106 uals who had had transcatheter closure of an atrial septal defect or patent foramen ovale to assess h

107 eatinine > or =2 mg/dL (OR 4.7), restrictive atrial septal defect (OR 2.7) and, in staged surgery, at

108 e an embryologic basis for the prevalence of atrial septal defects (ostium primum and secundum), vent

109 No children with secundum atrial septal defect, patent ductus arteriosus, or pulmo

110 uch as the transcatheter closure of secundum atrial septal defects, patent foramen ovale, patent duct

111 ed patients immediately prior to an elective atrial septal defect repair procedure.

112 ting surgery for congenital heart disease (9 atrial septal defect repair, 4 Fontan, 2 Mustard, 2 Senn

113 eak (prior Mustard procedure), closure of an atrial septal defect, repair of partial anomalous pulmon

114 t of the TARP syndrome, talipes equinovarus, atrial septal defect, Robin sequence, and persistent lef

115 tations, but not a mutation causing secundum atrial septal defects (S52F), demonstrated impaired prot

116 Periostin null mice exhibit atrial septal defects, structural abnormalities of the A

117 Sinus venosus atrial septal defect (SVASD) differs from secundum atria

118 g man with IAA associated with sinus venosus atrial septal defect (SVD) and partial anomalous pulmona

119 Sinus venosus atrial septal defect (SVD) is underdiagnosed with transt

120 of great vessels, ventricular septal defect, atrial septal defect, tetralogy of Fallot, coarctation o

121 g these tools, specifically in patients with atrial septal defects, tetralogy of Fallot, single ventr

122 mid-to-long-term data for device closure of atrial septal defects, the incidence of late cardiac ero

123 ccluder for Percutaneous Closure of Secundum Atrial Septal Defects; this study was approved by the Fo

124 reports the pilot in vivo study to create an atrial septal defect through the use of extracardiac app

125 ting on children after closure of a secundum atrial septal defect through the use of surgery (n=26) o

126 y the type of defect, from a low of 4.7% for atrial septal defects to a high of 28% for hypoplastic l

127 2 patients without prior diagnosis of PFO or atrial septal defect undergoing surgery at the Cleveland

128 Closure of large atrial septal defects using the Amplatzer device is safe

129 Sudden death after surgery for atrial septal defect, ventricular septal defect, tetralo

130 ry for 2 cohorts: (1) all patients with CHD (atrial septal defect, ventricular septal defect, tetralo

131 An atrial septal defect was created in dogs by blade septos

132 An atrial septal defect was present in 67 patients (88%) pr

133 In 9 of 10 canines, an atrial septal defect was produced, and shunting across t

134 A large atrial septal defect was the only structural heart disea

135 Under real-time ultrasound guidance, atrial septal defects were successfully created with ext

136 s decreased between 1990 and 2011 except for atrial septal defects, which increased significantly.

137 Closure of atrial septal defect with the AMPLATZER Septal Occluder

138 Pathology of the hearts showed atrial septal defects with minimal damage to surrounding